Yu-Chi Chiu

Dr. Yu-Chi Chiu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YCYu-Chi Chiu
Yu-Chi Chiu
SHShiang-Fen Huang
Shiang-Fen Huang
KYKwok-Woon Yu
Kwok-Woon Yu
YLYu-Chin Lee
Yu-Chin Lee
JFJia-Yih Feng
Jia-Yih Feng
WSWei-Juin Su
Wei-Juin Su
Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis (MDRTB) treatment. However, the unreliable results obtained from traditional susceptibility testing limits its usefulness in clinical settings. The detection of pncA gene mutations is a potential surrogate of PZA susceptibility testing, especially in MDRTB isolates. The impact of genotypes of M. tuberculosis in pncA gene mutations also remains to be clarified.

19 December 2013 in Respirology Case Reports
Verified
Journal Article
Open access
PDF file
WLWei‐Yang Lin
Wei‐Yang Lin
YCYu-Chi Chiu
Yu-Chi Chiu
Acquired nonmalignant tracheoesophageal fistula (TEF) is a rare clinical condition with multiple etiologies, although post-intubation injury is the most common cause. TEFs can be fatal if left untreated due to devastating pulmonary complications caused by tracheobronchial contamination and poor nutrition. Herein, we present a case of complete healing of a post-intubation TEF under conservative treatment in a ventilator-dependent patient, and review previous studies regarding the treatment of acquired nonmalignant TEFs.

2 November 2020 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
CWChiao-En Wu
Chiao-En Wu
CCChing-Fu Chang
Ching-Fu Chang
LKLiao Kou-Sheng
Liao Kou-Sheng
JCJu Chiang
Ju Chiang
YCYu-Chi Chiu
Yu-Chi Chiu
YCYu-Chi Chiu
Yu-Chi Chiu
Background. PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression. Materials and Methods. Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8th edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression. Results. Measurements of PD-L1 expression levels with Dako22C3 and Dako28-8 were comparable while SP142 showed lower levels of PD-L1 expression. The overall agreement between Dako22C3 and Dako28-8 was 82.2 and 91.6 for both 1 and 50 TPS cut-offs, respectively. The above findings were confirmed by Cohens kappa. In addition, we found that PD-L1 expression was significantly associated with advanced N stage but not with T and M stages. Conclusion. Dako22C3 and Dako28-8 showed comparable results in assessing PD-L1 levels. Future prospective studies are needed to validate these findings. N stage may be a good predictor for PD-L1 expression.

1 February 2021 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
HHHsiao-Feng Huang
Hsiao-Feng Huang
YCYu-Chi Chiu
Yu-Chi Chiu
CHChun-Jen Hunag
Chun-Jen Hunag

1 March 2026 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
CCCheng-Hsun Chuang
Cheng-Hsun Chuang
HHHsiao-Hsuan Huang
Hsiao-Hsuan Huang
YWYi-Syuan Wu
Yi-Syuan Wu
Chia-Hung ChenChia-Hung Chen
Chia-Hung Chen
SWShun-Long Weng
Shun-Long Weng
KLKuang-Wen Liao
Kuang-Wen Liao
Identifying the tumor-associated antigens (TAAs) overexpressed in a subgroup of tumor patients is a substantial challenge for cancer treatment. Although there are several methods based on the concept of differential expression, there is a lack of proper algorithms based on the heterogeneous transcriptome expression for exploring effective TAAs. Here, we propose an algorithm, TAPINTO, to objectively predict overexpressed TAAs whose expression is heterogeneous in cancer patients. This algorithm exploits the dispersion of expression in a subgroup of patients to create 3 quantitative parameters (the specific average expression, frequency, and fold change) for evaluating potential TAAs and has a good performance compared with other approaches. Based on these parameters, TAPINTO successfully identified HER2, a famous therapeutic target, and other potential TAAs (CXCL9, KCNJ3, SQLE, MMP11, and SLC7A2) in breast cancer; moreover, these parameters were dramatically consistent with the trend of clinical outcomes (objective response rate, progression-free survival, and serious adverse effects) of therapeutic antibodies. The ability of TAPINTO to capture heterogeneous expression patterns among patients was further validated in cancer hallmarks, subtypes, and prognosis. This study suggests that this novel method will enable potential TAAs to facilitate the subgroup of patients for diagnosis, prognostication, and therapy to overcome the tumor heterogeneity.

12 December 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
Chia-Hung ChenChia-Hung Chen
Chia-Hung Chen
YCYu-Chi Chiu
Yu-Chi Chiu
KHKai-Yao Huang
Kai-Yao Huang
HHHsiao-Hsuan Huang
Hsiao-Hsuan Huang
TKTa-Wei Kuo
Ta-Wei Kuo
KLKuang-Wen Liao
Kuang-Wen Liao
Background: Short peptide epitopes are valuable for mechanistic studies, yet their intrinsic low immunogenicity and lack of commercial antibodies hinder rapid antibody generation. Methods: We developed a reproducible, sequence-level workflow combining cross-species/structural triage, independent MHC-I/II prioritization, and conservative heteroclitic-style substitutions to enhance predicted MHC affinity while preserving native epitope features. Using visfatin as a model, two optimized fragments were conjugated to KLH and tested in mice for antibody titers, isotype profiles, and binding kinetics. Results: Mutant peptides improved MHC-binding prediction, elicited stronger antibody titers, and promoted isotype maturation (increased IgG1). Importantly, antibodies maintained measurable binding to wild-type sequences, indicating preserved cross-recognition. Similar effects were reproduced with additional antigens. Conclusions: This proof-of-concept study, based on small exploratory mouse cohorts (n = 3 per group), demonstrates that strategic, minimal sequence edits can significantly enhance peptide immunogenicity while preserving native epitope recognition. This streamlined workflow provides a low-barrier route to generate epitope-directed antibodies when commercial reagents are unavailable.